SERPASS 100 MG 20 TAB

Each Serpass 100 mg film-coated tablet contains sertraline hydrochloride 111.92 mg equivalent to sertraline 100 mg.

64.00 EGP

Purchase this product now and earn 64 Points!

SERPASS 100 MG 20 TAB; sertraline , antidepressants .

SERPASS 100 MG 20 TAB

ACTIVE-INGREDIENT OF SERPASS 100 MG

Each Serpass 100 mg film-coated tablet contains sertraline hydrochloride 111.92 mg equivalent to sertraline 100 mg.

INDICATION OF SERPASS 100 MG 

Serpass is indicated for the treatment of : Major depressive episodes. Prevention of recurrence of major depressive episodes. Panic disorder, with or without agoraphobia. Obsessive compulsive disorder (OCD) in adults and paediatric patients aged 6-17 years. Social anxiety disorder. Post-traumatic stress disorder (PTSD).

DOSAGE OF SERPASS 100 MG 

Follow all directions given to you by your pharmacist or doctor carefully . They may differ from the information contained in this leaflet

Ask your pharmacist or doctor for help if you do not understand the instructions on the box .

The recommended dose is : –

Serpass should be administered once daily with or without food, either in the morning or evening. Initial treatment: Depression and OCD: Serpass treatment should be started at a dose of 50 mg/day. Panic Disorder, PTSD, and Social Anxiety disorder. Therapy should be initiated at 25 mg/day. After one week, the dose should be increased to 50 mg once daily. This dosage regimen has been shown to reduce the frequency of early treatment emergent side effects characteristic of panic disorder. Titration: Depression, OCD, panic disorder, social anxiety disorder and PTSD. Patients not responding to a 50 mg dose may benefit from dose increases. Dose changes should be made in steps of 50 mg at intervals of at least one week, up to a maximum of 200 mg/day. Changes in dose should not be made more frequently than once per week given the 24-hour elimination half life of sertraline. The onset of therapeutic effect may be seen within 7 days. However, longer periods are usually necessary to demonstrate therapeutic response, especially in OCD. Maintenance : Dosage during longterm therapy should be kept at the lowest effective level, with subsequent adjustment depending on therapeutic response. Depression : Longer-term treatment may also be appropriate for prevention of recurrence of major depressive episodes (MDE). In most of the cases, the recommended dose in prevention of recurrence of MDE is the same as the one used during current episode. Patients with depression should be treated for a sufficient period of time of at least 6 months to ensure they are free from symptoms. Panic disorder and OCD: Continued treatment in panic disorder and OCD should be evaluated regularly, as relapse prevention has not been shown for thses disorders. Paediatric population: Children and adolescents with obsessive compulsive disorder: Age 13-17 years: Initially 50 mg once daily. Age 6-12 years: Initially 25 mg once daily. The dosage may be increased to 50 mg once daily after one week. Subsequent doses may be increased in case of less than desired response in 50 mg increments over a period of some weeks, as needed. The maximum dosage is 200 mg daily . However, the generally lower body weights of children compared to those of adults should be taken into consideration when increasing the dose from 50 mg. Dose changes should occur at intervals of less than one week. Efficacy is not shown in paediatric major depressive disorder. No data is available for children under 6 years of age. use in elderly : Elderly should be doses carefully, as elderly may be more at risk for hyponatraemia . Use in hepatic impairment: The use of sertraline in patients with hepatic disease should be approached with caution. A lower or less frequent dose should be used in patients with hepatic impairment. Sertraline should not be used in cases of severe hepatic impairment as no clinical data are available. Use in renal impairment: No dosage adjustment is necessary in patients with renal impairment. Withdrawal symptoms seen on discontinuation of sertraline: Abrupt discontinuation should be avoided. When stopping treatment with sertraline the dose should be gradually reduced over a period of at least one to two weeks in order to reduce the risk of withdrawal reactions. If intolerable symptoms occur following a decrease in the dose of upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose , but at a more gradual rate.

OVER-DOSAGE OF SERPASS 100 MG 

Toxicity: Sertraline has a margin of safety dependent on patient population and/or concomitant medication. Deaths have been reported involviing overdoses of sertraline, alone or in combination with other drugs and/or alcohol. Therefore, any overdosage should be medically treated aggressively. Symptoms: Symptoms of overdose include serotonin-mediated side effects such as somnolence, gastrointestinal disturbances (e.g nausea and vomiting), tachycardia, tremor, agitation and dizziness. Coma has been reported although less frequently. QTc prolongation/Torsade de pointes has been reported following sertraline overdose; therefore, ECG-monitoring is recommended in all ingestions of sertralline overdoses. Management: There are no specific antidotes to sertraline. It is recommended to establish and maintain an airway and, if necessary, ensure adequate oxygenation and ventilation. Activated charcoal, which may be used with a cathartic, may be as, or more effective than lavage, and should be considered in treating overdose. Induction of emesis is not recommended. cardiac (e.g. ECG) and vital sign monitoring is also recommended, along with general symptomatic and supportive measures. Due to the large volume of distribution of sertraline, forced diuresis, dialysis, haemoperfusion and exchange transfusion are unlikely to be of benefit.

CONTRA-INDICATION OF SERPASS 100 MG 

Hypersensitivity to the active substance or any of the excipients. Concomitant treatment with irreversible monoamine oxidase inhibitors (MAOIs) is contraindicated due to the risk of serotonin syndrome with symptoms such as agitation, tremor and hyperthermia. Sertraline must not be initiated for at least 14 days after discontinuation of treatment with an irreversible MAOI. Sertraline must be discontinued for at least 7 days before starting treatment with an irreversible MAOI. Concomitant intake of pimozide is contraindicated.

STORAGE OF SERPASS 100 MG 

Store at a temperature not exceeding 30 °C, in a dry place.
PACK OF SERPASS 100 MG 20 TAB
Boxes of 20 tablets each.
SERPASS 100 MG 20 TAB MANUFACTURED BY
GLOBAL NAPI PHARMACEUTICALS 2nd Industrial Zone, 6th of October City – Egypt www.globalnapi.com

https://www.webmd.com/drugs/2/drug-1/sertraline-oral/details

https://www.gardeniapharmacy.com/category/medicine-2/

Form

Gender

How to use

Reviews

There are no reviews yet.

Show reviews in all languages (1)

Be the first to review “SERPASS 100 MG 20 TAB”

Your email address will not be published.

Shopping Cart
Don`t copy text!
Scroll to Top